Jeffrey Dierks Sells 1,629 Shares of Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Stock

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) insider Jeffrey Dierks sold 1,629 shares of Harmony Biosciences stock in a transaction dated Monday, January 27th. The stock was sold at an average price of $38.02, for a total transaction of $61,934.58. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Jeffrey Dierks also recently made the following trade(s):

• On Friday, January 24th, Jeffrey Dierks sold 13,125 shares of Harmony Biosciences stock. The shares were sold at an average price of $37.31, for a total transaction of $489,693.75.
• On Tuesday, January 21st, Jeffrey Dierks sold 1,123 shares of Harmony Biosciences stock. The stock was sold at an average price of $40.00, for a total value of $44,920.00.
• On Wednesday, January 15th, Jeffrey Dierks sold 10,507 shares of Harmony Biosciences stock. The shares were sold at an average price of $37.01, for a total value of $388,864.07.

Harmony Biosciences Trading Up 1.0 %

NASDAQ HRMY opened at $38.82 on Thursday. The firm’s fifty day moving average price is $35.20 and its 200 day moving average price is $35.22. Harmony Biosciences Holdings, Inc. has a 12 month low of $28.14 and a 12 month high of $41.61. The company has a debt-to-equity ratio of 0.28, a current ratio of 3.24 and a quick ratio of 3.20. The company has a market capitalization of $2.21 billion, a price-to-earnings ratio of 18.40, a price-to-earnings-growth ratio of 0.51 and a beta of 0.78.

Harmony Biosciences (NASDAQ:HRMY) last posted its earnings results on Tuesday, October 29th. The company reported $0.79 EPS for the quarter, topping analysts’ consensus estimates of $0.64 by $0.15. Harmony Biosciences had a return on equity of 23.16% and a net margin of 17.98%. The business had revenue of $186.00 million for the quarter, compared to analysts’ expectations of $184.07 million. During the same quarter in the previous year, the firm earned $0.63 earnings per share. The business’s revenue was up 16.0% compared to the same quarter last year. On average, sell-side analysts expect that Harmony Biosciences Holdings, Inc. will post 2.43 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several analysts recently issued reports on the stock. HC Wainwright restated a “buy” rating and issued a $75.00 price objective on shares of Harmony Biosciences in a report on Monday. Oppenheimer reaffirmed an “outperform” rating and issued a $59.00 price objective (up from $56.00) on shares of Harmony Biosciences in a research note on Wednesday, October 30th. Needham & Company LLC restated a “buy” rating and set a $52.00 target price on shares of Harmony Biosciences in a report on Monday, January 13th. Cantor Fitzgerald increased their price target on shares of Harmony Biosciences from $51.00 to $58.00 and gave the stock an “overweight” rating in a research report on Wednesday, October 30th. Finally, Mizuho increased their target price on shares of Harmony Biosciences from $42.00 to $52.00 and gave the stock an “outperform” rating in a report on Thursday, October 10th. Eight research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average price target of $55.00.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the company. Mirae Asset Global Investments Co. Ltd. lifted its stake in Harmony Biosciences by 21.2% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,056 shares of the company’s stock valued at $80,000 after buying an additional 360 shares during the last quarter. GAMMA Investing LLC increased its holdings in shares of Harmony Biosciences by 92.6% in the 4th quarter. GAMMA Investing LLC now owns 907 shares of the company’s stock valued at $31,000 after acquiring an additional 436 shares during the period. CWM LLC raised its position in Harmony Biosciences by 111.7% in the 3rd quarter. CWM LLC now owns 1,469 shares of the company’s stock valued at $59,000 after purchasing an additional 775 shares during the last quarter. KBC Group NV boosted its stake in Harmony Biosciences by 79.9% during the 4th quarter. KBC Group NV now owns 1,844 shares of the company’s stock worth $63,000 after purchasing an additional 819 shares during the period. Finally, Hedeker Wealth LLC grew its position in Harmony Biosciences by 1.2% during the 4th quarter. Hedeker Wealth LLC now owns 76,203 shares of the company’s stock worth $2,622,000 after purchasing an additional 916 shares during the last quarter. Hedge funds and other institutional investors own 86.23% of the company’s stock.

Harmony Biosciences Company Profile

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.